Publications by authors named "K Vidqvist"
The data on the effects of tofacitinib on soluble proteins in patients with rheumatoid arthritis (RA) is currently very limited. We analyzed how tofacitinib treatment and thus inhibition of the Janus kinase-signal transducer and activation of transcription pathway affects the in vivo levels of inflammation-related plasma proteins in RA patients. In this study, 16 patients with active RA [28-joint disease activity score (DAS28) >3.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the reasons for treatment interruptions in patients using TNF-inhibitors (infliximab and adalimumab) and how these interruptions impact immunisation and treatment switching.
- Based on a survey of 370 patients from various hospitals in Finland, it was found that treatment interruptions were significantly linked to immunisation and more common among those treated for rheumatic diseases.
- The most frequent interruption cause was infections, and such interruptions can lead to increased immunisation risk and a greater need for switching medications, highlighting the need for careful clinical decision-making.
Article Synopsis
- * It was found that immunization (anti-drug antibodies, or ADAb) affected drug efficacy, with 11% of patients having detectable ADAb, most notably in those using certolizumab pegol.
- * Methotrexate use was shown to reduce the risk of ADAb formation, while low drug trough levels were common and linked to higher disease activity, highlighting the importance of monitoring drug levels in treated patients.
Objective: Many cytokines involved in RA activate the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Therapeutic drugs that inhibit these pathways are being developed for RA. To investigate disease-related alterations in the activity of JAK-STAT pathways in RA, we studied the expression and activation of STAT1 and STAT3 in unstimulated and cytokine-stimulated cells and determined the levels of circulating cytokines.
View Article and Find Full Text PDFObjectives: To investigate the use of DMARDs and biologic treatments and disease activity in patients with JIA referred to the adult rheumatology clinic and to provide further information regarding the need for long-term rheumatologic care.
Methods: We studied the data of 154 patients retrospectively from hospital records if they met the following criteria: diagnosis of JIA and at least one visit to the adult rheumatologic unit. Previous and current antirheumatic treatment, duration of biologic therapy and disease activity were recorded.